Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis – SC410

It is estimated that over 20% of the American population has Non-Alcoholic Fatty Liver Disease (NAFLD). NAFLD is defined as having greater than 5% liver fat accumulation. NAFLD may continue to develop into NASH resulting in liver fibrosis and eventual liver failure. There is no approved therapy for NAFLD or Non-Alcoholic Steatohepatitis (NASH). One of the most vulnerable populations are children with Type II diabetes who will likely develop liver disease if NAFLD remains untreated.

There are over 100,000 diabetic children with NAFLD. Several million adults, many with diabetes also have NAFLD. In addition, there are over 200,000 Americans with NASH with an estimated 8% developing severe liver disease leading to transplant surgery. The market size for products to treat NAFLD and NASH exceeds $1 billion.

Treatment options for NAFLD and NASH include life-style changes. There are no drugs approved for either indication.

Problem: There are no approved therapies for patients with either NAFLD or NASH.

Current Treatment: Other than life-style changes for NAFLD, there are no known cures or treatment for NAFLD or NASH.

ALT™ Solution: ALT™ super bioavailable formulation has been shown to reduce liver fat, reduce triglycerides, restore healthy glucose levels and improve liver enzymes in animal models. In addition, the overall weight of the animals decreased with equal caloric intake.


Japan Mice Study

Mouse Study g

Google+   Likedin